About this Research Topic
Diabetic retinopathy (DR) and macular oedema (DMO), and neovascular age-related macular degeneration (nAMD) are two major vascular diseases that cause retinal blindness or visual impairment. Currently, we have treatment for both – laser therapy and anti-VEGF injection for DR, and anti-VEGF and laser procedures for the nAMD. But these treatment modalities are not without complications and side effects. In DR, pan-retinal photocoagulation causes night
blindness and constricting visual fields, and stopping anti-VEGF therapy has resulted fast worsening of DR. In nAMD, anti-VEGF treatment has resulted a new challenge - the emergence of post-treatment geographic atrophy (GA). The only possible approach to combat DR and DMO and AMD is early diagnosis and targeted therapies at earlier stages than currently practiced. Growing body of literature shows that diabetic retinal neurodegeneration (DRN) occurs before the appearance of clinical DR or DMO whose diagnosis is based on vasculopathy, so is the case in AMD. There is function lesions or compromise happening before the clinical stages.
Therefore, through this special edition of the publication we are aiming to collect and highlight firstly the possible diagnostic procedures of pre-clinical DR and DMO and early-stage AMD, and
secondly, any targeted therapies of early-stage DR or DRN, and AMD. This especial issue will also highlight the importance and role of stem cell and gene-based therapies.
This Research Topic aims at bringing together the novel ideas and thoughts on the diagnostic and management strategies of early-stage DR and DMO and AMD. These approaches may include any current diagnostic methods that can be used to diagnose early-stage diseases, approaches currently under clinical trials, imaging technologies or bio-markers, those are targeted at treating early-stage DR or DMO, and AMD. Similarly, treatment modalities may include current treatment suitably be used to treat early-stage DR/DMO or AMD, treatments under clinical trials, including stem cell therapies or gene- based therapy.
Manuscripts on any theme targeting pre-clinical or early-stage DR and DMO, and early-stage AMD, mainly intermediate AMD.
● Diagnostic strategies, imaging techniques or bio-markers, targeting pre-clinical DR and DMO, and early and intermediate AMD.
● Therapies targeted at the diabetic retinal neurodegeneration, pre-clinical DR or early-stage DR and DMO, and early to intermediate AMD.
● Any manuscripts on stem cell and gene-based therapies of AMD or DR and DMO.
blindness and constricting visual fields, and stopping anti-VEGF therapy has resulted fast worsening of DR. In nAMD, anti-VEGF treatment has resulted a new challenge - the emergence of post-treatment geographic atrophy (GA). The only possible approach to combat DR and DMO and AMD is early diagnosis and targeted therapies at earlier stages than currently practiced. Growing body of literature shows that diabetic retinal neurodegeneration (DRN) occurs before the appearance of clinical DR or DMO whose diagnosis is based on vasculopathy, so is the case in AMD. There is function lesions or compromise happening before the clinical stages.
Therefore, through this special edition of the publication we are aiming to collect and highlight firstly the possible diagnostic procedures of pre-clinical DR and DMO and early-stage AMD, and
secondly, any targeted therapies of early-stage DR or DRN, and AMD. This especial issue will also highlight the importance and role of stem cell and gene-based therapies.
This Research Topic aims at bringing together the novel ideas and thoughts on the diagnostic and management strategies of early-stage DR and DMO and AMD. These approaches may include any current diagnostic methods that can be used to diagnose early-stage diseases, approaches currently under clinical trials, imaging technologies or bio-markers, those are targeted at treating early-stage DR or DMO, and AMD. Similarly, treatment modalities may include current treatment suitably be used to treat early-stage DR/DMO or AMD, treatments under clinical trials, including stem cell therapies or gene- based therapy.
Manuscripts on any theme targeting pre-clinical or early-stage DR and DMO, and early-stage AMD, mainly intermediate AMD.
● Diagnostic strategies, imaging techniques or bio-markers, targeting pre-clinical DR and DMO, and early and intermediate AMD.
● Therapies targeted at the diabetic retinal neurodegeneration, pre-clinical DR or early-stage DR and DMO, and early to intermediate AMD.
● Any manuscripts on stem cell and gene-based therapies of AMD or DR and DMO.
Keywords: Diabetic retinal neurodegeneration; diagnosis of early-stage AMD; functional lesion in diabetic retinopathy; pre-clinical diabetic retinopathy; targeted therapies.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
